Cognitive impairment induced by delta9- tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors

PLoS Biology

Volumn 13, Issue 7, 2015, Pages

  Viñals, Xavier ^a   Moreno, Estefanía ^b,c   Lanfumey, Laurence ^d   Cordomí, Arnau ^e   Pastor, Antoni ^f   De La Torre, Rafael ^f   Gasperini, Paola ^b,c,g   Navarro, Gemma ^b,c   Howell, Lesley A ^g   Pardo, Leonardo ^e   Lluís, Carmen ^b,c   Canela, Enric I ^b,c   McCormick, Peter J ^b,c,g   Maldonado, Rafael ^a   Robledo, Patricia ^a,f  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSERM   (France)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CELL PENETRATING PEPTIDE; DRONABINOL; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; SEROTONIN 2A RECEPTOR; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; AMNESIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; EMBRYO; EXPOSURE; FEMALE; HETEROMERIZATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MALE; MEMORY DISORDER; MOLECULAR INTERACTION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; RECEPTOR BINDING; RECEPTOR UPREGULATION; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY; ANALGESIA; ANIMAL; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED; DIMERIZATION; DRUG EFFECTS; HEK293 CELL LINE; HYPOTHERMIA; LOCOMOTION; METABOLISM; TRANSGENIC MOUSE;

CANNABIS; MUS;

AMNESIA; ANALGESIA; ANIMALS; ANXIETY; BRAIN; COGNITION DISORDERS; DIMERIZATION; DORSAL RAPHE NUCLEUS; DRONABINOL; HEK293 CELLS; HUMANS; HYPOTHERMIA; LOCOMOTION; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTOR, CANNABINOID, CB1; RECEPTOR, SEROTONIN, 5-HT2A;

EID: 84938703167     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1002194     Document Type: Article

References (96)

1. Puighermanal E, Busquets-Garcia A, Maldonado R, Ozaita A. Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philos Trans R Soc Lond B Biol Sci. 2012; 367: 3254–3263. 4 doi: 10.1098/rstb.2011.0384 PMID: 23108544
2. Castellano C, Rossi-Arnaud C, Cestari V, Costanzi M. Cannabinoids and memory: animal studies. Curr Drug Targets CNS Neurol Disord. 2003; 2: 389–402. PMID: 14683467
3. Rodríguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, et al. Corticotropinreleasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther. 1996; 276: 56–64. PMID: 8558457
4. Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol. 2008; 13: 196–212. doi: 10.1111/j.1369-1600.2008.00104.x PMID: 18422832
5. Maldonado R, Berrendero F, Ozaita A, Robledo P. Neurochemical basis of cannabis addiction. Neuroscience. 2011; 181: 1–17. doi: 10.1016/j.neuroscience.2011.02.035 PMID: 21334423
6. Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol. 2005; 509–554. PMID: 16596786
7. Valjent E, Mitchell JM, Besson M-J, Caboche J, Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol. 2002; 135: 564–578. PMID: 11815392
8. Cheer JF, Cadogan AK, Marsden CA, Fone KC, Kendall DA. Modification of 5-HT2 receptor mediated behavior in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology. 1999; 38: 533–541. PMID: 10221757
9. Darmani NA. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. Pharmacol Biochem Behav. 2001; 68: 311–317. PMID: 11267636
10. Gorzalka BB, Hill MN, Sun JC. Functional role of the endocannabinoid system and AMPA/kainate receptors in 5-HT2A receptor-mediated wet dog shakes. Eur J Pharmacol. 2005; 516: 28–33. PMID: 15913602
11. Aso E, Renoir T, Mengod G, Ledent C, Hamon M, Maldonado R, et al. Lack of CB1 receptor activity impairs serotonergic negative feedback. J Neurochem. 2009; 109: 935–944. doi: 10.1111/j.1471-4159. 2009.06025.x PMID: 19302195
12. Mato S, Aso E, Castro E, Martín M, Valverde O, Maldonado R, et al. CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors. J Neurochem. 2007; 103: 2111–2120. PMID: 17944876
13. Parrish JC, Nichols DE. Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. J Neurochem. 2006; 99: 1164–1175. PMID: 17010161
14. Best AR, Regehr WG. Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. J Neurosci Off J Soc Neurosci. 2008; 28: 6508–6515.
15. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013; 64: 21–47. doi: 10.1146/annurev-psych-113011-143739 PMID: 22804774
16. Bombardi C, Di Giovanni G. Functional anatomy of 5-HT2A receptors in the amygdala and hippocampal complex: relevance to memory functions. Exp Brain Res. 2013; 230: 427–439. doi: 10.1007/s00221-013-3512-6 PMID: 23591691
17. De Almeida J, Mengod G. Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT(2A) receptors in human and monkey prefrontal cortex. J Neurochem. 2007; 103: 475–486. PMID: 17635672
18. Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998; 83: 393–411. PMID: 9460749
19. Bodor AL, Katona I, Nyíri G, Mackie K, Ledent C, Hájos N, et al. Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci Off J Soc Neurosci. 2005; 25: 6845–6856.
20. Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex N Y N 1991. 2007; 17: 175–191.
21. Tsou K, Mackie K, Sañudo-Peña MC, Walker JM. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience. 1999; 93: 969–975. PMID: 10473261
22. Jakab RL, Goldman-Rakic PS. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A. 1998; 95: 735–740. PMID: 9435262
23. Miner L A. H, Backstrom JR, Sanders-Bush E, Sesack SR. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience. 2003; 116: 107–117. PMID: 12535944
24. Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in muopioid receptor patches of the rat Caudate putamen nucleus. J Neurosci Off J Soc Neurosci. 2001; 21: 823–833.
25. Pazos A, Cortés R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 1985; 346: 231–249. PMID: 4052777
26. Mengod G, Pompeiano M, Martínez-Mir MI, Palacios JM. Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res. 1990; 524: 139–143. PMID: 2400925
27. Weber ET, Andrade R. Htr2a Gene and 5-HT(2A) Receptor Expression in the Cerebral Cortex Studied Using Genetically Modified Mice. Front Neurosci. 2010; 4: 36. doi: 10.3389/fnins.2010.00036 PMID: 20802802
28. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989; 251: 238–246. PMID: 2571717
29. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007; 53: 439–452. PMID: 17270739
30. Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2003; 28: 1760–1769.
31. Gleason KA, Birnbaum SG, Shukla A, Ghose S. Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Transl Psychiatry. 2012; 2: e199.
32. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl). 2002; 163: 111–117.
33. Martin LP, Jackson DM, Wallsten C, Waszczak BL. Electrophysiological comparison of 5-Hydroxytryptamine1A receptor antagonists on dorsal raphe cell firing. J Pharmacol Exp Ther. 1999; 288: 820–826. PMID: 9918594
34. Orejarena MJ, Lanfumey L, Maldonado R, Robledo P. Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behavior. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP. 2011; 14: 927–940.
35. Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology. 2009; 56 Suppl 1: 235–243. doi: 10.1016/j.neuropharm.2008.07.018 PMID: 18691603
36. Mendizábal V, Zimmer A, Maldonado R. Involvement of kappa/dynorphin system in WIN 55,212–2 selfadministration in mice. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2006; 31: 1957–1966.
37. Sanchis-Segura C, Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol. 2006; 11: 2–38. PMID: 16759333
38. Schroder R, Schmidt J, Blattermann S, Peters L, Janssen N, Grundmann M, et al. Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc. 2011; 6: 1748–1760. doi: 10.1038/nprot.2011.386 PMID: 22015845
39. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol. 2003; 15: 91–119. PMID: 14977366
40. Ferré S, Casadó V, Devi LA, Filizola M, Jockers R, Lohse MJ, et al. G Protein—Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives. Pharmacol Rev. 2014; 66: 413–434. doi: 10.1124/pr.113.008052 PMID: 24515647
41. Ferré S. The GPCR heterotetramer: challenging classical pharmacology. Trends Pharmacol Sci. 2015; 36:145–152. doi: 10.1016/j.tips.2015.01.002 PMID: 25704194
42. Bouvier M, Heveker N, Jockers R, Marullo S, Milligan G. BRET analysis of GPCR oligomerization: newer does not mean better. Nat Meth. 2007; 4: 3–4.
43. Issad T, Jockers R. Bioluminescence Resonance Energy Transfer to Monitor Protein-Protein Interactions. Transmembrane Signaling Protocols. New Jersey: Humana Press; pp. 193–210. http://www.springerlink.com/content/j7144l226708t8xk/#section=86243&page=12&locus=35
44. Söderberg O, Leuchowius K-J, Gullberg M, Jarvius M, Weibrecht I, Larsson L-G, et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods San Diego Calif. 2008; 45: 227–232.
45. Mocanu M-M, Váradi T, Szöllősi J, Nagy P. Comparative analysis of fluorescence resonance energy transfer (FRET) and proximity ligation assay (PLA). PROTEOMICS. 2011; 11: 2063–2070. doi: 10.1002/pmic.201100028 PMID: 21480528
46. Baba K, Benleulmi-Chaachoua A, Journe A-S, Kamal M, Guillaume J-L, Dussaud S, et al. Heteromeric MT1/MT2 Melatonin Receptors Modulate Photoreceptor Function. Sci Signal. 2013; 6: ra89. doi: 10.1126/scisignal.2004302 PMID: 24106342
47. González S, Moreno-Delgado D, Moreno E, Pérez-Capote K, Franco R, Mallol J, et al. Circadian-Related Heteromerization of Adrenergic and Dopamine D4 Receptors Modulates Melatonin Synthesis and Release in the Pineal Gland. Schibler U, editor. PLoS Biol. 2012; 10: e1001347. doi: 10.1371/journal.pbio.1001347 PMID: 22723743
48. Kern A, Albarran-Zeckler R, Walsh HE, Smith RG. Apo-Ghrelin Receptor Forms Heteromers with DRD2 in Hypothalamic Neurons and Is Essential for Anorexigenic Effects of DRD2 Agonism. Neuron. 2012; 73: 317–332. doi: 10.1016/j.neuron.2011.10.038 PMID: 22284186
49. Moreno E, Vaz SH, Cai N-S, Ferrada C, Quiroz C, Barodia SK, et al. Dopamine-Galanin Receptor Heteromers Modulate Cholinergic Neurotransmission in the Rat Ventral Hippocampus. J Neurosci Off J Soc Neurosci. 2011; 31: 7412–7423.
50. Moreno E, Moreno-Delgado D, Navarro G, Hoffmann HM, Fuentes S, Rosell-Vilar S, et al. Cocaine Disrupts Histamine H3 Receptor Modulation of Dopamine D1 Receptor Signaling: σ1-D1-H3 Receptor Complexes as Key Targets for Reducing Cocaine’s Effects. J Neurosci Off J Soc Neurosci. 2014; 34: 3545–3558.
51. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. Nature. 2013; 494: 185–194. doi: 10.1038/nature11896 PMID: 23407534
52. Rasmussen SGF, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature. 2011; 477: 549–555. doi: 10.1038/nature10361 PMID: 21772288
53. Rasmussen SGF, Choi H-J, Fung JJ, Pardon E, Casarosa P, Chae PS, et al. Structure of a nanobodystabilized active state of the β(2) adrenoceptor. Nature. 2011; 469: 175–180. doi: 10.1038/nature09648 PMID: 21228869
54. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature. 2012; 485: 321–326. doi: 10.1038/nature10954 PMID: 22437502
55. Guitart X, Navarro G, Moreno E, Yano H, Cai N-S, Sanchez M, et al. Functional Selectivity of Allosteric Interactions within GPCR oligomers: the Dopamine D1-D3 Receptor Heterotetramer. Mol Pharmacol. 2014; mol.114.093096.
56. Lee LTO, Ng SYL, Chu JYS, Sekar R, Harikumar KG, Miller LJ, et al. Transmembrane peptides as unique tools to demonstrate the in vivo action of a cross-class GPCR heterocomplex. FASEB J. 2014; fj.13–246868.
57. Ferre S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, et al. Building a new conceptual framework for receptor heteromers. Nat Chem Biol. 2009; 5: 131–134. doi: 10.1038/nchembio0309-131 PMID: 19219011
58. Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, Yadav PN, et al. CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci. 2010; 13: 622–629. doi: 10.1038/nn.2529 PMID: 20383137
59. Lüttgen M, Ove Ogren S, Meister B. Chemical identity of 5-HT2A receptor immunoreactive neurons of the rat septal complex and dorsal hippocampus. Brain Res. 2004; 1010: 156–165. PMID: 15126129
60. Franklin JM, Mathew M, Carrasco GA. Cannabinoid-induced upregulation of serotonin 2A receptors in the hypothalamic paraventricular nucleus and anxiety-like behaviors in rats. Neurosci Lett. 2013; 548: 165–169. doi: 10.1016/j.neulet.2013.05.039 PMID: 23721787
61. Weisstaub NV, Zhou M, Lira A, Lambe E, González-Maeso J, Hornung J-P, et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science. 2006; 313: 536–540. PMID: 16873667
62. Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdère P, Caccia S, et al. 5-HT2A and 5- HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2002; 26: 311–324.
63. López-Giménez JF, Mengod G, Palacios JM, Vilaró MT. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907. Naunyn Schmiedebergs Arch Pharmacol. 1997; 356: 446–454. PMID: 9349630
64. Kabli N, Nguyen T, Balboni G, O’Dowd BF, George SR. Antidepressant-like and anxiolytic-like effects following activation of the μ-δ opioid receptor heteromer in the nucleus accumbens. Mol Psychiatry. 2014; 19:986–994. doi: 10.1038/mp.2013.115 PMID: 24061495
65. Steindel F, Lerner R, Häring M, Ruehle S, Marsicano G, Lutz B, et al. Neuron-type specific cannabinoid-mediated G protein signalling in mouse hippocampus. J Neurochem. 2013; 124: 795–807. doi: 10.1111/jnc.12137 PMID: 23289830
66. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology. 2004; 47 Suppl 1: 227–241. PMID: 15464140
67. Chiang Y-C, Lo Y-N, Chen J-C. Crosstalk between dopamine D2 receptors and cannabinoid CB1 receptors regulates CNR1 promoter activity via ERK1/2 signaling. J Neurochem. 2013; 127: 163–176. doi: 10.1111/jnc.12399 PMID: 23952963
68. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci. 2004; 5: 173–183. PMID: 14976517
69. Rivera P, Arrabal S, Cifuentes M, Grondona JM, Pérez-Martín M, Rubio L, et al. Localization of the cannabinoid CB1 receptor and the 2-AG synthesizing (DAGLα) and degrading (MAGL, FAAH) enzymes in cells expressing the Ca(2+)-binding proteins calbindin, calretinin, and parvalbumin in the adult rat hippocampus. Front Neuroanat. 2014; 8: 56. doi: 10.3389/fnana.2014.00056 PMID: 25018703
70. Franco R, Martínez-Pinilla E, Ricobaraza A, McCormick PJ. Challenges in the development of heteromer-GPCR-based drugs. Prog Mol Biol Transl Sci. 2013; 117: 143–162. doi: 10.1016/B978-0-12-386931-9.00006-4 PMID: 23663968
71. Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, et al. Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs. Cell. 2011; 147: 1011–1023. doi: 10.1016/j.cell.2011.09.055 PMID: 22118459
72. Nygaard R, Zou Y, Dror RO, Mildorf TJ, Arlow DH, Manglik A, et al. The Dynamic Process of β2-Adrenergic Receptor Activation. Cell. 2013; 152: 532–542. doi: 10.1016/j.cell.2013.01.008 PMID: 23374348
73. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease—successes and failures. FEBS J. 2013; 280: 1918–1943. doi: 10.1111/febs.12260 PMID: 23551849
74. González-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, et al. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci Off J Soc Neurosci. 2003; 23: 8836–8843.
75. Fiorica-Howells E, Hen R, Gingrich J, Li Z, Gershon MD. 5-HT(2A) receptors: location and functional analysis in intestines of wild-type and 5-HT(2A) knockout mice. Am J Physiol Gastrointest Liver Physiol. 2002; 282: G877–893. PMID: 11960784
76. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999; 96: 5780–5785. PMID: 10318961
77. Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schütz G, et al. Genetic dissection of behavioral and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol. 2007; 5: e269. PMID: 17927447
78. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci. 2009; 12: 1152–1158. doi: 10.1038/nn.2369 PMID: 19648913
79. Mackie K. Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. Int J Obes 2005. 2006; 30 Suppl 1: S19–23.
80. Mongeau R, Martin CBP, Chevarin C, Maldonado R, Hamon M, Robledo P, et al. 5-HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment. J Neurochem. 2010; 115: 438–449. doi: 10.1111/j.1471-4159.2010.06932.x PMID: 20796171
81. Pertovaara A, Almeida A. Chapter 13 Descending inhibitory systems. Handb Clin Neurol. 2006; 81: 179–192. doi: 10.1016/S0072-9752(06)80017-5 PMID: 18808835
82. Palazzo E, Luongo L, de Novellis V, Rossi F, Maione S. The Role of Cannabinoid Receptors in the Descending Modulation of Pain. Pharmaceuticals. 2010; 3: 2661–2673.
83. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J. 1998; 17: 886–897. PMID: 9463367
84. Eddy NB, Leimbach D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther. 1953; 107: 385–393. PMID: 13035677
85. Soria G, Mendizábal V, Touriño C, Robledo P, Ledent C, Parmentier M, et al. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2005; 30: 1670–1680.
86. Castañé A, Maldonado R, Valverde O. Role of different brain structures in the behavioral expression of WIN 55,212–2 withdrawal in mice. Br J Pharmacol. 2004; 142: 1309–1317. PMID: 15265804
87. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985; 14: 149–167. PMID: 2864480
88. Vandermaelen CP, Aghajanian GK. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res. 1983; 289: 109–119. PMID: 6140982
89. Lanfumey L, Pardon MC, Laaris N, Joubert C, Hanoun N, Hamon M, et al. 5-HT1A autoreceptor desensitization by chronic ultramild stress in mice. Neuroreport. 1999; 10: 3369–3374. PMID: 10599847
90. Haj-Dahmane S, Hamon M, Lanfumey L. K+ channel and 5-hydroxytryptamine1A autoreceptor interactions in the rat dorsal raphe nucleus: an in vitro electrophysiological study. Neuroscience. 1991; 41: 495–505. PMID: 1714550
91. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. Gulf Professional Publishing; 2004.
92. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry. 2011; 70: 479–486. doi: 10.1016/j.biopsych.2011.04.022 PMID: 21684528
93. Ferrada C, Moreno E, Casadó V, Bongers G, Cortés A, Mallol J, et al. Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol. 2009; 157: 64–75. doi: 10.1111/j.1476-5381.2009.00152.x PMID: 19413572
94. Callén L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cortés A, Mallol J, et al. Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain. J Biol Chem. 2012; 287: 20851–20865. doi: 10.1074/jbc.M111.335273 PMID: 22532560
95. Moreno E, Hoffmann H, Gonzalez-Sepúlveda M, Navarro G, Casadó V, Cortés A, et al. Dopamine D1- histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J Biol Chem. 2011; 286: 5846–5854. doi: 10.1074/jbc.M110.161489 PMID: 21173143
96. Chen T-W, Wardill TJ, Sun Y, Pulver SR, Renninger SL, Baohan A, et al. Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature. 2013; 499: 295–300. doi: 10.1038/nature12354 PMID: 23868258